PTC Therapeutics (PTCT) Receives Media Sentiment Score of 0.14

News coverage about PTC Therapeutics (NASDAQ:PTCT) has been trending somewhat positive on Sunday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PTC Therapeutics earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.5466078322321 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the news stories that may have impacted Accern Sentiment’s analysis:

PTC Therapeutics (NASDAQ:PTCT) opened at $30.20 on Friday. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.04 and a quick ratio of 2.90. The company has a market cap of $1,248.42, a PE ratio of -14.52 and a beta of 1.71. PTC Therapeutics has a one year low of $8.12 and a one year high of $31.25.

PTC Therapeutics (NASDAQ:PTCT) last issued its earnings results on Tuesday, March 6th. The biopharmaceutical company reported $0.03 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.17. The business had revenue of $78.00 million for the quarter, compared to the consensus estimate of $78.59 million. PTC Therapeutics had a negative net margin of 40.64% and a negative return on equity of 50.75%. The company’s revenue for the quarter was up 209.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.78) EPS. sell-side analysts anticipate that PTC Therapeutics will post -1.4 earnings per share for the current fiscal year.

Several brokerages recently commented on PTCT. Zacks Investment Research upgraded shares of PTC Therapeutics from a “hold” rating to a “buy” rating and set a $31.00 price target on the stock in a report on Saturday, March 10th. Barclays reiterated an “equal weight” rating and set a $24.00 price target (up from $18.00) on shares of PTC Therapeutics in a report on Wednesday, March 7th. William Blair reiterated a “hold” rating on shares of PTC Therapeutics in a report on Wednesday, March 7th. Citigroup upped their price target on shares of PTC Therapeutics from $24.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, February 21st. Finally, Credit Suisse Group reiterated a “buy” rating and set a $28.00 price target on shares of PTC Therapeutics in a report on Tuesday, January 30th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $23.57.

In other PTC Therapeutics news, CEO Stuart Walter Peltz sold 2,230 shares of the company’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $18.03, for a total value of $40,206.90. Following the transaction, the chief executive officer now directly owns 26,646 shares in the company, valued at approximately $480,427.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 2,719 shares of company stock worth $48,848 over the last 90 days. Insiders own 8.10% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “PTC Therapeutics (PTCT) Receives Media Sentiment Score of 0.14” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.

Insider Buying and Selling by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply